RxDoctor Payments DataLook up a doctor →

Moazzam Habib, MD

Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1639270721

Payments from drug & device makers

$29,049in general payments, 2019–2025

Across 1,217 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$11K
  • Novo Nordisk$2K
  • Mannkind Corporation$2K
  • Corcept Therapeutics$1K
  • Amgen$1K
  • AstraZeneca$1K
  • plus $10K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC96$11,423
Novo Nordisk144$1,933
Mannkind Corporation96$1,533
Corcept Therapeutics79$1,385
Amgen(2 entities)72$1,324
AstraZeneca(2 entities)59$1,141
AbbVie(2 entities)58$953
Endo Pharmaceuticals Inc.74$877
Bayer46$738
Sanofi-aventis U.S. LLC43$698
Esperion Therapeutics, Inc.48$672
Merck54$668
Abbott46$607
Xeris Pharmaceuticals, Inc.28$521
Novartis22$440
Insulet Corporation14$314
Amneal Pharmaceuticals LLC19$303
Medtronic(2 entities)13$292
Boehringer Ingelheim16$259
Zealand Pharma US, Inc.17$241
Endo USA, Inc.11$239
Antares Pharma, Inc.14$219
Currax Pharmaceuticals LLC20$191
Sun Pharmaceutical Industries Inc.4$167
Valeritas, Inc.13$158
Arbor Pharmaceuticals, Inc.9$141
Radius Health, Inc.9$137
Regeneron Healthcare Solutions, Inc.7$105
Recordati_rare_diseases_inc.7$100
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$92
Clarus Therapeutics Inc.8$88
Pfizer5$85
Halozyme Inc4$78
Kowa Pharmaceuticals America, Inc.6$76
Companion Medical, Inc.4$75
Amarin Pharma, Inc.4$73
Takeda Pharmaceuticals U.S.A., Inc.2$70
Johnson & Johnson5$68
Azurity Pharmaceuticals, Inc.4$66
IBSA Pharma Inc.4$56
Avvisto Therapeutics, LLC3$46
Aytu Biopharma, Inc.3$42
Averitas Pharma Inc.2$41
Tandem Diabetes Care, Inc.2$40
Sequel Med Tech, LLC2$32
Acerus Pharmaceuticals Corporation2$25
Boston Scientific1$24
Neurocrine Biosciences, Inc.1$24
Senseonics, Incorporated1$22
Cequr Corporation1$22
Shire North American Group Inc1$21
Amryt Pharma Holdings Ltd1$20
Dexcom, Inc.1$17
GRT US Holding, Inc.1$16
EUSA Pharma (US) LLC1$15
Verity Pharmaceuticals Inc.1$14
Ipsen Biopharmaceuticals, Inc1$13
Lifescan, Inc.1$11

How this compares

$29,049 in reported general payments places this provider in the 80th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana →

Medicare billing

Part B allowed, 2024
$66,596
Medicare patients
220
Services billed
4,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Indianapolis

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →